Syncona

Thesis

FTSE 250 life sciences investment company founding and building global leaders in cell, gene therapy, and biologics.

Stages

GrowthSeedSeries ASeries B

Sectors

BiotechHealthcare/MedtechLife SciencesDeep Tech/Hard Science

Current fund: Syncona Limited (LSE: SYNC) · 2012 · $£288M capital pool + £765M life science investments
AUM: $£1.05B NAV

Israeli medical-device innovation house that invents, patents, and builds proprietary medtech startups.…

Growth-stage investor backing category-leading cannabis and cannabis-adjacent companies navigating evolving regulation.…

AI and robotics applied to transform foundational industries vertical by vertical.…